A Comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation.

Department of Nephrology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Transplantation (Impact Factor: 3.78). 01/2006; 80(11):1572-7. DOI: 10.1097/
Source: PubMed

ABSTRACT Although most protocols for ABO-incompatible kidney transplantation have employed splenectomy, its utility is unproven. The aim of the current study was to compare the outcomes of ABO-incompatible living donor kidney transplantation with splenectomy versus a protocol involving intensive posttransplant antibody monitoring to maintain low levels of antiblood group antibody.
We retrospectively studied all ABO-incompatible living donor kidney transplants at our institution between September 1999 and November 2004 (n=34). Prior to May 2003, all patients were included in a protocol involving pretransplant plasmapheresis and splenectomy at the time of transplant (n=23). After May 2003, splenectomy was not performed and a protocol that involved pretransplant anti-CD20 antibody and a more intensive posttransplant plasmapheresis regiment aimed at maintaining low levels of antiblood group antibody during the first 2 weeks following transplantation was utilized (n=11).
Patient and graft survival was similar in the two groups. Humoral rejection occurred in 18% nonsplenectomized and 30% of splenectomized patients (P=0.68). Humoral rejection correlated with the baseline antibody titer in both groups. Individuals with elevated baseline antibody titer (> or =1:256) appear to be at high risk for humoral rejection regardless of protocol used. Antiblood group antibody levels 3 and 12 months after transplantation were similar in both groups.
Splenectomy is not essential for successful ABO-incompatible kidney transplantation, although individuals with high baseline antidonor blood group antibody titers are at high risk for humoral rejection. The use of intensive posttransplant monitoring may help prevent antibody-mediated graft damage.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rituximab, a monoclonal antibody directed against the CD20 molecule found on pre-B cells and mature B cells (but not on plasma cells), was introduced in the late 1990s for the treatment of non-Hodgkin's lymphoma. Recently, this antibody has been used to treat autoimmune diseases, especially those associated with a prominent humoral component and with potentially pathogenic autoantibodies. Small cohort studies have indicated that rituximab could have an important role in the management of these disorders. Rituximab has also been utilized in the transplant setting, to diminish levels of alloreactive antibodies in highly sensitized patients, to manage ABO-incompatible transplants, and to treat rejection associated with B cells and antibodies. The exact mechanism by which rituximab exerts its effects in autoimmunity and transplantation remains unclear, as specific autoantibody or alloantibody levels often seem not to diminish in parallel with clinical improvement. A role for rituximab in depleting B cells and compromising their antigen-presenting function seems likely; rituximab might also inhibit T-cell activation. A synergistic effect has been noted in vitro following administration of corticosteroids to B-cell lines, with accentuation of B-cell cytotoxicity; this observation might be relevant to certain studies, as some regimens have utilized both agents simultaneously. This article reviews the current use of rituximab in renal disease and transplantation, and includes discussion of the drug's potential role in novel therapeutic protocols.
    Nature Clinical Practice Nephrology 05/2006; 2(4):221-30. DOI:10.1038/ncpneph0133 · 6.08 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Over the past several years, protocols have been developed to allow patients with antibody against either donor blood group (ABO-incompatible) or donor HLA antigens (positive cross-match) to undergo successful kidney transplantation. Important factors determining the development of hyperacute rejection, humoral rejection and long-term graft survival have been defined. In this review, the clinical experience with ABO-incompatible and positive cross-match kidney transplantation at Mayo Clinic, Rochester are described with an emphasis on both patient management issues and gaps in our current knowledge in this emerging field.
    International Congress Series 07/2006; 1292:113-119. DOI:10.1016/j.ics.2006.03.057
  • [Show abstract] [Hide abstract]
    ABSTRACT: ABO-incompatible kidney and liver transplants can be performed successfully by depleting anti-A or anti-B isoagglutinins pretransplant and by suppressing their development posttransplant. With these protocols, humoral rejection can be avoided. Recovery of isohemagglutinin antibody levels without humoral rejection suggests accommodation, the ability of an organ allograft to survive in the presence of anti-graft antibodies and complement, may be the protective mechanism preventing late antibody-mediated rejection. This may be related to the ability of endothelial cells, the target of antibody-mediated rejection, to upregulate protective genes, including those encoding heme oxygenase-1 (HO-1) that then block the proinflammatory response of the endothelial cells and thereby rejection. Induced expression of HO-1 in the endothelial cells of the graft before transplantation may prevent apoptosis of those cells after transplantation, and prevent the generation of endothelial cell-based inflammation that leads to rejection. Experimental and clinical studies in ABO-incompatible models will be required to examine this hypothesis, and determine whether carbon monoxide (CO) might be able to modulate antibody-mediated rejection after ABO-incompatible transplantation.
    International Congress Series 07/2006; 1292:53-60. DOI:10.1016/j.ics.2006.03.060